Sichuan Haimeng Zhisen Biopharmaceutical

Sichuan Haimeng Zhisen Biopharmaceutical is a Chengdu-based pharmaceutical company founded in 2019 that specializes in the Marketing Authorization Holder (MAH) business model. It was the first company in Sichuan Province to receive the Drug Manufacturing License B certificate, allowing it to manage the full lifecycle of drug products from research and development to commercialization through strategic contract manufacturing partnerships. The company's portfolio focuses on diverse dosage forms, including inhalation solutions, injections, and eye drops, with a pipeline of over 20 programs targeting respiratory, gastrointestinal, and metabolic conditions. While the company has successfully commercialized several products, it recently faced regulatory challenges in 2025 regarding manufacturing oversight, leading to temporary disqualification from national centralized procurement programs.